GlassScriptPhysician profile
Jacqueline A Ross
NPI 1295055150
$130,769.66
in general payments reported to CMS, 2019-2025
46 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,991 · 2020: $3,209 · 2021: $4,035 · 2022: $7,319 · 2023: $18K · 2024: $48K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $9,400 · Travel and Lodging: $7,631 · Honoraria: $4,223 · Education: $29.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,910.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,022.29 |
| Food and Beverage | $9,400.09 |
| Travel and Lodging | $7,631.20 |
| Honoraria | $4,223.00 |
| Education | $29.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $63,868.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $21,557.15 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $19,625.27 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Blueprint Medicines Corporation | $7,484.91 | 2020-2025 | Ayvakit |
| Incyte Corporation | $5,985.23 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $3,036.27 | 2019-2025 | |
| Dermavant Sciences, INC. | $1,787.08 | 2024 | Vtama |
| Optinose US, INC. | $1,298.18 | 2019-2023 | |
| Shionogi INC | $790.75 | 2020 | |
| Abbvie INC. | $601.87 | 2022-2024 | Rinvoq |
| Grifols USA, LLC | $478.96 | 2019-2025 | Xembify |
| Pfizer INC. | $475.91 | 2019-2025 | |
| Astrazeneca Uk Limited | $465.00 | 2025 | Tezspire |
| Glaxosmithkline, LLC. | $402.35 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $386.64 | 2019-2025 | Haegarda, Andembry, Hizentra |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $336.48 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $331.33 | 2020-2022 | |
| Amgen INC. | $264.90 | 2022-2025 | Tezspire, Actimmune |
| Lilly USA, LLC | $174.60 | 2024-2025 | Ebglyss, Taltz |
| Takeda Pharmaceuticals U.S.A., INC. | $171.38 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Biocryst US Sales Co., LLC | $144.39 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $111.28 | 2019-2023 | Auvi-Q |
| Alk-Abello, INC | $101.46 | 2020-2021 | |
| Octapharma USA, INC. | $94.72 | 2019-2023 | Panzyga |
| Leo Pharma INC. | $93.20 | 2022-2024 | Adbry |
| Covis Pharma Gmbh | $74.64 | 2021 | |
| Pharming Healthcare, INC. | $64.70 | 2022-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $61.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.61 | 2021 | |
| Irhythm Technologies, INC. | $50.57 | 2024 | Zio Xt Patch, Zio Monitor |
| Bio Products Laboratory USA, INC. | $45.59 | 2019-2022 | |
| Shire North American Group INC | $43.21 | 2019 | |
| Galderma Laboratories, L.P. | $34.97 | 2025 | Nemluvio |
| Insmed, INC. | $34.57 | 2025 | Arikayce |
| Organon LLC | $28.53 | 2025 | Vtama |
| Phadia US INC. | $28.50 | 2020 | |
| Sanofi-Aventis U.S. LLC | $26.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.77 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $18.45 | 2025 | Neffy |
| Azurity Pharmaceuticals, INC. | $17.99 | 2025 | Alvesco |
| Gc Biopharma USA, INC. | $17.86 | 2025 | Alyglo |
| Ionis Pharmaceuticals, INC. | $17.10 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $17.00 | 2025 | Sajazir |
| Merck Sharp & Dohme LLC | $16.58 | 2023 | |
| Horizon Therapeutics Plc | $14.42 | 2022 | |
| Uswm, LLC | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.